title: Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization.
abstract: Transcatheter arterial chemoembolization (TACE) is an effective therapy for hepatocellular carcinoma (HCC). However, acute kidney injury (AKI) may occur after TACE due to the contrast agent and cytotoxic anticancer drugs used in this procedure. Post-TACE AKI is not an unusual event, and may adversely affect patient outcome. Coexisting situations including cirrhosis, renal insufficiency, diabetes and hypertension play a role in the development of HCC, and may predispose patients to AKI after TACE. Most post-TACE are transient and reversible, while prolonged AKI may predict a decreased survival. The best strategy to manage post-TACE AKI is prevention. Patients, before undergoing TACE, should be carefully assessed. In this study, we reviewed the current literature published in English about the incidence rate, risk factors, management and prognosis of AKI in patients with HCC undergoing TACE for a better understanding of this complication.
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Chen Xiao
authors.initials: CX
authors.lastname: Hong
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Lv Wen
authors.initials: LW
authors.lastname: Lv
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Liu Zhong
authors.initials: LZ
authors.lastname: Hua
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Shen
authors.initials: S
authors.lastname: Bo
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Cao Xue
authors.initials: CX
authors.lastname: Sen
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Nie Yu
authors.initials: NY
authors.lastname: Xin
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Yu Jia
authors.initials: YJ
authors.lastname: Wei
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Xu Jia
authors.initials: XJ
authors.lastname: Rui
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Ding Xiao
authors.initials: DX
authors.lastname: Qiang
authors.affiliation: Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032. China.
authors.forename: Zou Jian
authors.initials: ZJ
authors.lastname: Zhou
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002404:Catheterization; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D019468:Disease Management; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Acute kidney injury; incidence; prevention; prognosis; risk factor; transcatheter arterial chemoembolization